Cargando…

Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma

Melanoma is one of the most fatal cancers, and its incidence is increasing worldwide. Thanks to the better understanding of the molecular mechanisms involved in the pathogenesis of melanoma, recently new targeted agents have been developed. In this article, we review the current state of knowledge o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russo, Irene, Zorzetto, Ludovica, Chiarion Sileni, Vanna, Alaibac, Mauro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332919/ https://www.ncbi.nlm.nih.gov/pubmed/30693134 http://dx.doi.org/10.1155/2018/5036213

Ejemplares similares

Melanoma M (Zero): Diagnosis and Therapy
por: Rastrelli, Marco, et al.
Publicado: (2013)

Altitude Effect on Cutaneous Melanoma Epidemiology in the Veneto Region (Northern Italy): A Pilot Study
por: Del Fiore, Paolo, et al.
Publicado: (2022)

Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
por: Valpione, Sara, et al.
Publicado: (2015)

Surgery and radiotherapy in the treatment of cutaneous melanoma
por: Testori, A., et al.
Publicado: (2009)

Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2021)

Vitamins and Melanoma
por: Russo, Irene, et al.
Publicado: (2015)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Immunomodulation in Cutaneous T Cell Lymphoma
por: Ferranti, Martina, et al.
Publicado: (2019)

RIPK3 and AXL Expression Study in Primary Cutaneous Melanoma Unmasks AXL as Predictor of Sentinel Node Metastasis: A Pilot Study
por: Nicolè, Lorenzo, et al.
Publicado: (2021)

Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
por: Plachouri, Kerasia-Maria, et al.
Publicado: (2023)

Primary Cutaneous B-Cell Lymphomas in Patients With Impaired Immunity
por: Russo, Irene, et al.
Publicado: (2020)

Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features
por: Del Fiore, Paolo, et al.
Publicado: (2022)

Editorial: Mechanisms of resistance to the targeted therapy and immunotherapy in cutaneous melanoma
por: Premi, Sanjay, et al.
Publicado: (2022)

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
por: Gençler, Bilgen, et al.
Publicado: (2016)

Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial
por: Guida, Michele, et al.
Publicado: (2003)

Advances in targeted therapy and immunotherapy for melanoma (Review)
por: Qin, Ziyao, et al.
Publicado: (2023)

Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study
por: Gullo, Giulia, et al.
Publicado: (2022)

Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
por: Nikolaou, Vasiliki, et al.
Publicado: (2023)

Cutaneous Lymphoma and Antibody-Directed Therapies
por: Sernicola, Alvise, et al.
Publicado: (2023)

Advances in Targeting Cutaneous Melanoma
por: Kasakovski, Dimitri, et al.
Publicado: (2021)

Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients
por: Rastrelli, Marco, et al.
Publicado: (2018)

Cutaneous and Noncutaneous Adverse Effects in Patients with Advanced Melanoma Receiving Immunotherapy
por: Yeung, Howa, et al.
Publicado: (2023)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
por: Chiarion-Sileni, Vanna, et al.
Publicado: (2006)

Report from the Melanoma Independent Board First Melanoma MIB Conference, 21–22 October 2013
por: Testori, A, et al.
Publicado: (2014)

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study
por: Del Vecchio, Michele, et al.
Publicado: (2023)

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014)

Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma
por: Guida, Michele, et al.
Publicado: (2022)

Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers
por: Spiliopoulou, Pavlina, et al.
Publicado: (2023)

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma
por: Hagen, Brenda, et al.
Publicado: (2014)

Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
por: Falcone, Italia, et al.
Publicado: (2020)

Editorial: Cutaneous manifestations of systemic disease
por: Sernicola, Alvise, et al.
Publicado: (2023)

Melanoma in Adolescents and Young Adults: Evaluation of the Characteristics, Treatment Strategies, and Prognostic Factors in a Monocentric Retrospective Study
por: Del Fiore, Paolo, et al.
Publicado: (2021)

A gene expression signature associated with survival in metastatic melanoma
por: Mandruzzato, Susanna, et al.
Publicado: (2006)

Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced Melanoma
por: Olszanski, Anthony J.
Publicado: (2014)

Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma
por: Valpione, Sara, et al.
Publicado: (2015)

The immune cell landscape of metastatic uveal melanoma correlates with overall survival
por: Tosi, Anna, et al.
Publicado: (2021)

Corrigendum: Melanoma in Adolescents and Young Adults (AYA): Evaluation of the Characteristics, Treatment Strategies, and Prognostic Factors in a Monocentric Retrospective Study
por: Del Fiore, Paolo, et al.
Publicado: (2021)

Anthropometry in the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Cutaneous melanoma and the immunotherapy revolution (Review)
por: Leonardi, Giulia C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ofbgue4kgrp969qefjon4o04i8